First Command Advisory Services Inc. Lowers Position in Johnson & Johnson (NYSE:JNJ)

First Command Advisory Services Inc. reduced its position in shares of Johnson & Johnson (NYSE:JNJFree Report) by 2.5% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 14,629 shares of the company’s stock after selling 377 shares during the period. First Command Advisory Services Inc.’s holdings in Johnson & Johnson were worth $2,313,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in JNJ. Blume Capital Management Inc. lifted its holdings in Johnson & Johnson by 2.6% in the first quarter. Blume Capital Management Inc. now owns 59,265 shares of the company’s stock valued at $9,375,000 after acquiring an additional 1,500 shares during the period. Financial Counselors Inc. increased its holdings in shares of Johnson & Johnson by 14.3% in the 1st quarter. Financial Counselors Inc. now owns 183,373 shares of the company’s stock valued at $29,008,000 after purchasing an additional 22,943 shares in the last quarter. Chase Investment Counsel Corp lifted its stake in shares of Johnson & Johnson by 3.5% in the first quarter. Chase Investment Counsel Corp now owns 3,739 shares of the company’s stock valued at $591,000 after purchasing an additional 128 shares during the period. Shoker Investment Counsel Inc. grew its position in Johnson & Johnson by 0.7% during the first quarter. Shoker Investment Counsel Inc. now owns 18,625 shares of the company’s stock worth $2,939,000 after buying an additional 127 shares during the period. Finally, Farrow Financial Inc. increased its holdings in Johnson & Johnson by 6.8% in the first quarter. Farrow Financial Inc. now owns 13,038 shares of the company’s stock valued at $2,062,000 after buying an additional 826 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

Johnson & Johnson stock opened at $149.41 on Thursday. The company has a current ratio of 1.17, a quick ratio of 0.94 and a debt-to-equity ratio of 0.36. The firm has a market capitalization of $359.58 billion, a P/E ratio of 9.31, a PEG ratio of 2.42 and a beta of 0.52. The stock has a fifty day moving average price of $147.93 and a 200 day moving average price of $153.56. Johnson & Johnson has a 52 week low of $143.13 and a 52 week high of $175.97.

Johnson & Johnson (NYSE:JNJGet Free Report) last released its earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.64 by $0.07. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The business had revenue of $21.38 billion for the quarter, compared to analysts’ expectations of $21.39 billion. During the same period last year, the company earned $2.68 earnings per share. The company’s quarterly revenue was up 2.3% on a year-over-year basis. Equities research analysts anticipate that Johnson & Johnson will post 10.62 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st were given a $1.24 dividend. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.19. This represents a $4.96 annualized dividend and a dividend yield of 3.32%. The ex-dividend date was Monday, May 20th. Johnson & Johnson’s dividend payout ratio (DPR) is 30.92%.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. The Goldman Sachs Group initiated coverage on Johnson & Johnson in a report on Thursday, May 30th. They set a “neutral” rating and a $160.00 price objective for the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research report on Monday, July 1st. Royal Bank of Canada restated an “outperform” rating and set a $175.00 target price on shares of Johnson & Johnson in a report on Monday, June 17th. Morgan Stanley lowered their price target on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 17th. Finally, StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Sunday, June 30th. Eight investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $174.07.

Check Out Our Latest Stock Report on Johnson & Johnson

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

Recommended Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.